Literature DB >> 9700534

In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.

K L Oakley1, C B Moore, D W Denning.   

Abstract

The in-vitro activity of the triazole antifungal agent voriconazole was compared with itraconazole and amphotericin B against 60 aspergillus isolates. Susceptibility tests were performed using two methods: a macrodilution and a microdulution method. For macrodilution methodology, geometric mean (GM) MIC values and ranges were 0.4 and 0.125-4 mg/L for voriconazole, 0.24 and 0.06-->16 mg/L for itraconazole, and 1.04 and 0.5-4 mg/L for amphotericin B. For the microdilution method, GM MICs and ranges were 0.66 and 0.125-2 mg/L for voriconazole, 0.27 and 0.06-->16 mg/L for itraconazole, and 1.62 and 0.25-32 mg/L for amphotericin B. In conclusion, voriconazole is active against Aspergillus spp. in vitro, and at similar concentrations to itraconazole.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700534     DOI: 10.1093/jac/42.1.91

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Voriconazole: in the treatment of invasive aspergillosis.

Authors:  Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B.

Authors:  C B Moore; C M Walls; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; S Nangia; J H Rex
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

4.  In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.

Authors:  R K Li; M A Ciblak; N Nordoff; L Pasarell; D W Warnock; M R McGinnis
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods.

Authors:  Maria José Linares; Guadalupe Charriel; Francisco Solís; Fernando Rodriguez; Ana Ibarra; M Casal
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 6.  Newer antifungal agents.

Authors:  Walid Abuhammour; Eyassu Habte-Gaber
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

Review 7.  Invasive aspergillosis caused by Aspergillus ustus: case report and review.

Authors:  P E Verweij; M F van den Bergh; P M Rath; B E de Pauw; A Voss; J F Meis
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

8.  Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience.

Authors:  Simone Cesaro; Liliana Strugo; Rita Alaggio; Giovanni Cecchetto; Luca Rigobello; Marta Pillon; Riccardo Cusinato; Luigi Zanesco
Journal:  Support Care Cancer       Date:  2003-09-13       Impact factor: 3.603

Review 9.  Mechanisms of triazole resistance in Aspergillus fumigatus.

Authors:  Ashley V Nywening; Jeffrey M Rybak; Phillip David Rogers; Jarrod R Fortwendel
Journal:  Environ Microbiol       Date:  2020-10-21       Impact factor: 5.491

10.  Voriconazole in the treatment of invasive mold infections in transplant recipients.

Authors:  J Fortún; P Martín-Dávila; M A Sánchez; V Pintado; M E Alvarez; A Sánchez-Sousa; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-24       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.